This title appears in the Scientific Report :
2021
Please use the identifier:
http://hdl.handle.net/2128/27586 in citations.
Please use the identifier: http://dx.doi.org/10.2967/jnumed.120.248278 in citations.
Treatment Monitoring of Immunotherapy and Targeted Therapy using 18 F-FET PET in Patients with Melanoma and Lung Cancer Brain Metastases: Initial Experiences
Treatment Monitoring of Immunotherapy and Targeted Therapy using 18 F-FET PET in Patients with Melanoma and Lung Cancer Brain Metastases: Initial Experiences
We investigated the value of O-(2-18F-fluoroethyl)-l-tyrosine (18F-FET) PET for treatment monitoring of immune checkpoint inhibition (ICI) or targeted therapy (TT) alone or in combination with radiotherapy in patients with brain metastasis (BM) since contrast-enhanced MRI often remains inconclusive....
Saved in:
Personal Name(s): | Galldiks, Norbert (Corresponding author) |
---|---|
Abdulla, Diana SY / Scheffler, Matthias / Wolpert, Fabian / Werner, Jan-Michael / Huellner, Martin W / Stoffels, Gabriele / Schweinsberg, Viola / Schlaak, Max / Kreuzberg, Nicole / Landsberg, Jennifer / Lohmann, Philipp / Ceccon, Garry / Baues, Christian / Trommer, Maike / Celik, Eren / Ruge, Maximilian I / Kocher, Martin / Marnitz, Simone / Fink, Gereon R / Tonn, Joerg-Christian / Weller, Michael / Langen, Karl-Josef / Wolf, Jürgen / Mauch, Cornelia | |
Contributing Institute: |
Physik der Medizinischen Bildgebung; INM-4 Kognitive Neurowissenschaften; INM-3 |
Published in: | Journal of nuclear medicine, 62 (2021) 4, S. 464-470 |
Imprint: |
New York, NY
Soc.
2021
|
DOI: |
10.2967/jnumed.120.248278 |
Document Type: |
Journal Article |
Research Program: |
ohne Topic |
Link: |
OpenAccess |
Publikationsportal JuSER |
Please use the identifier: http://dx.doi.org/10.2967/jnumed.120.248278 in citations.
We investigated the value of O-(2-18F-fluoroethyl)-l-tyrosine (18F-FET) PET for treatment monitoring of immune checkpoint inhibition (ICI) or targeted therapy (TT) alone or in combination with radiotherapy in patients with brain metastasis (BM) since contrast-enhanced MRI often remains inconclusive. Methods: We retrospectively identified 40 patients with 107 BMs secondary to melanoma (n = 29 with 75 BMs) or non–small cell lung cancer (n = 11 with 32 BMs) treated with ICI or TT who had 18F-FET PET (n = 60 scans) for treatment monitoring from 2015 to 2019. Most patients (n = 37; 92.5%) had radiotherapy during the course of the disease. In 27 patients, 18F-FET PET was used to differentiate treatment-related changes from BM relapse after ICI or TT. In 13 patients, 18F-FET PET was performed for response assessment to ICI or TT using baseline and follow-up scans (median time between scans, 4.2 mo). In all lesions, static and dynamic 18F-FET PET parameters were obtained (i.e., mean tumor-to-brain ratios [TBR], time-to-peak values). Diagnostic accuracies of PET parameters were evaluated by receiver-operating-characteristic analyses using the clinical follow-up or neuropathologic findings as a reference. Results: A TBR threshold of 1.95 differentiated BM relapse from treatment-related changes with an accuracy of 85% (P = 0.003). Metabolic responders to ICI or TT on 18F-FET PET had a significantly longer stable follow-up (threshold of TBR reduction relative to baseline, ≥10%; accuracy, 82%; P = 0.004). Furthermore, at follow-up, time to peak in metabolic responders increased significantly (P = 0.019). Conclusion: 18F-FET PET may add valuable information for treatment monitoring in BM patients treated with ICI or TT. |